Beta Bionics Q1 revenue up 36% to $17.6M; net loss widens; raises 2025 guidance

Beta Bionics, Inc.

2025-Q1 EPS reported -$0.93 revenue$17,639,000

Net sales $17.6M (+36% YoY); DME $13.8M (+14%), PBP $3.8M (+360%).
Installed customer base 19,151 (+291%); 3,853 new patient starts (+48%).
Gross margin 50.9% (down 482 bps); operating loss $18.6M; net loss $28.7M.
Cash and investments $295.5M as of March 31, 2025.
Raised full-year 2025 annual guidance (specific numeric targets not in excerpt).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.